Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NNFA GMP meeting

This article was originally published in The Tan Sheet

Executive Summary

The National Nutritional Foods Association recently met with the Office of Management & Budget to discuss the forthcoming good manufacturing practices for dietary supplements, NNFA CEO David Seckman says. The trade group set up the meeting to "represent the association's interests" as well as stress the importance of "expediting the review process," Seckman explained. NNFA reiterated views previously expressed to FDA about important aspects of the proposed rule such as expiration dating for dietary supplements, he adds. OMB did not indicate when the final rule will be released. GMPs were received by OMB on Oct. 25; the Executive Branch office has a 90-day period to review the final rule before sending it back to FDA for publication (1"The Tan Sheet" Oct. 31, 2005, p. 9)...

You may also be interested in...



Supplement GMPs Received By OMB For 90-Day Clearance Review

FDA's goal of issuing a final rule on dietary supplement current Good Manufacturing Practices by the end of the year may be within reach

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel